Vor Biopharma Inc. 13D

RA Capital and affiliates hold a roughly 19.9% capped stake in Vor Biopharma and modestly increased their position via warrant exercise while disclosing the resignation of their board representative without stating new activist intentions.

RA Capital Management, L.P., together with its affiliated fund and principals Peter Kolchinsky and Rajeev Shah, reports beneficial ownership capped at approximately 19.9% of Vor Biopharma Inc.’s common stock (12,937,855 shares counted for beneficial ownership purposes due to a warrant blocker), following the July 16, 2026 cashless exercise of pre-funded warrants into 2,099,787 shares; the amendment reflects this incremental increase in ownership and notes the July 6, 2026 resignation of RA-affiliated director Andrew Levin from Vor’s board, but does not articulate new activist plans or a change in strategic intent beyond maintaining a large, capped position.

Filing Facts

CIK

1817229

Ticker

VOR

Form

13D

Source Type

fda

Accession

0001346824-26-000197

Alert Tier

7